Skip to content

Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy

Evaluation of the Efficacy of a New Extensively Hydrolyzed Formula in Infants With Cow's Milk Protein Allergy

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01998074
Acronym
Paradice
Enrollment
Unknown
Registered
2013-11-28
Start date
Unknown
Completion date
Unknown
Last updated
2013-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Food Sensitivity, Milk Hypersensitivity, Protein Allergy

Keywords

Cow's Milk protein Allergy

Brief summary

The aim of the study is to show the efficacy, tolerance and nutritional adequacy of a newly developed hydrolyzed rice formula in infants with a proven cow's milk protein allergy.

Interventions

DIETARY_SUPPLEMENTextensively hydrolyzed rice protein formula

Sponsors

United Pharmaceuticals
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
2 Weeks to 6 Months
Healthy volunteers
No

Inclusion criteria

* Infants between 2 weeks and 6 months old * In whom cow's Milk Protein Allergy has been proved by a food challenge performed during the previous month

Exclusion criteria

* Exclusively breast fed infants * Preterm infants * Infants already fed with an extensively hydrolyzed formula with no improvement of the symptoms. * Infants fed an amino acid based formula * Infants who had an anaphylactic reaction in the past

Design outcomes

Primary

MeasureTime frame
Clinical improvement of symptoms of cow's milk protein allergy, through the use of a validated scoreat 4 weeks

Secondary

MeasureTime frame
Clinical improvement of symptoms of cow's milk protein allergy, through the use of a validated scoreat 3 months
Growth (weight, height, head circumference)1 month

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026